Search Videos and More
News
Clinical Trial Points to Treatment Advances for Glioma Patients for First Time in Decades
In the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, vorasidenib significantly prolonged progression free survival and delayed radiation and chemotherapy for patients with Grade 2 IDH-mutant glioma.
Podcast
Season 2, Episode 6: Big Data, AI, and Cancer Research
As our universe of knowledge expands, sometimes incrementally and more often, exponentially, its new dimensions create new challenges. The more we know, the better our tools are, the more choices we have. And that's great, but it's hard to distill mountains of patient data, clinical trials, therapies, discoveries, and a boatload of externalities.
Podcast
Season 2, Episode 5: With a Little Help From My Friends: Combination Immunotherapy
If there is such a thing as a holy grail in cancer research, a secret spell or golden ring that can ward off any and all forms of the disease, it probably lives somewhere in the realm of immunotherapy.
News
Institute Research Shines at Society of Gynecologic Oncology Annual Meeting
Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.
News
Three-Drug Combination Slows Progression of Advanced Kidney Cancer
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.
News
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
News
Seeking Signs of Synergy: The Origins of PARP and PI3K Inhibitors
Pairing multiple drugs together to synergistically destroy a patient's tumor has become a common approach to cancer treatment
News
Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer
The data presented here align with the initial results of the primary analysis of the CLEAR trial. This supports the use of lenvatinib plus pembrolizumab as a standard-of-care first-line treatment for patients with renal cell carcinoma.
Symposium
2023 ASPHO Conference Highlights
Review Dana-Farber Faculty presentations from the ASPHO 2023 conference.
News
Dana-Farber Research Publication 05.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Course
10th Annual Cancer Disparities Research Symposium
Dana-Farber Cancer Institute's Christopher Lathan, MD, MS, MPH, and Dana-Farber/Harvard Cancer Center's Karen Burns White host the Annual Cancer Disparities Research Symposium in recognition of National Minority Cancer Awareness.
News
High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival
ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies